clinical trial · NCT05491525
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
Urovant Sciences GmbH·phase3·recruiting·n = 85
Neurogenic Detrusor OveractivityVibegron
brief summary
The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
started
Oct 12, 2022
primary completion
Jan 1, 2027
completion
Sep 1, 2027
last updated
Jul 3, 2024
official title
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol